AstraZeneca And Huma On Digital’s Value For Pharma

Digital tools have long been of interest to pharma for their potential to transform many aspects of drug development, leading to many collaborations between pharma and medtech firms. Here, two companies that have been working together to develop a series of software-based tools for monitoring patients – AstraZeneca and Huma – discuss the value of these partnerships and their potential challenges.  

Data synchronization of health book between smartwatch and smartphone in male hands
• Source: Shutterstock

Digital tools for recording data can transform patient care from a series of episodic snapshots into a continuum, allowing health care providers to deliver the treatments needed faster. Naturally, these tools could be very valuable to pharmaceutical companies – both in pre-market research and post-market surveillance – and many of the biggest players in the sector have either been acquiring or collaborating with digital-only companies to augment their own product portfolios.

One such example of a collaboration between a big pharma company and a medtech is that of AstraZeneca PLC...

More from AI

More from Digital Technologies